معرفی
Jay Kranzler is an Adjunct Professor of Management and Organizations at the Leonard N. Stern School of Business, New York University, a position he has held since 2011. He also holds an adjunct appointment at NYU Langone School of Medicine, reflecting his dual expertise in business and medical sciences. With a career spanning nearly four decades in the life sciences sector, Dr. Kranzler bridges academic instruction with real-world biotechnology leadership.
Dr. Kranzler's educational background includes advanced training in both medicine and science:
- MD, PhD in Psychiatry/Pharmacology, Yale University (1985)
- MS, MPhil in Pharmacology, Yale University (1983)
- BA in Pre-Medical Studies, Yeshiva University (1979)
His research and professional interests center on the intersection of biotechnology, pharmacology, and psychiatry. With deep experience in drug, device, and diagnostic development, he brings practical insights into the structure and strategy of the biotechnology industry. His teaching focuses on the business dynamics of life science innovation, particularly through his course on the Biotechnology Industry: Structure and Strategy.
While no recent publications are listed, his career reflects a sustained engagement with translational research and commercialization in the pharmaceutical and biotech sectors.
Dr. Kranzler has received no explicitly mentioned scientific awards in the provided text.
Throughout his career, Dr. Kranzler has advised numerous organizations and mentored professionals in the biotech space, though no formal student advisees are listed. He has held executive roles including CEO of Cytel Corporation and Cypress Bioscience, and currently leads Urica Therapeutics. From 2009 to 2013, he served as Vice President of External R&D Innovation and Strategic Investments at Pfizer, where he shaped global research partnerships. He also maintains an active consulting practice serving pharmaceutical companies, biotech startups, and investors, and currently serves on the boards of seven life science companies.
Though not tied to a formal laboratory or research team at NYU, Dr. Kranzler is deeply embedded in the life science innovation ecosystem through his corporate leadership, board memberships, and strategic advisory roles, effectively functioning as a bridge between academic research and commercial development.
